Zacks Research Upgrades Armata Pharmaceuticals (NYSEAMERICAN:ARMP) to “Hold”

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, HC Wainwright lifted their price objective on Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Price Performance

Shares of Armata Pharmaceuticals stock opened at $8.46 on Monday. Armata Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $16.34. The company has a market capitalization of $310.57 million, a P/E ratio of -1.09 and a beta of 1.31. The business has a 50 day moving average price of $10.25 and a 200 day moving average price of $8.20.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The company had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.74 million. As a group, research analysts expect that Armata Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in shares of Armata Pharmaceuticals by 233.2% during the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock worth $120,000 after buying an additional 8,198 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Armata Pharmaceuticals during the 4th quarter worth $108,000. Millennium Management LLC acquired a new stake in shares of Armata Pharmaceuticals during the 4th quarter worth $164,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Armata Pharmaceuticals during the 4th quarter worth $177,000. Finally, SeaCrest Wealth Management LLC increased its holdings in shares of Armata Pharmaceuticals by 17.3% during the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after buying an additional 6,034 shares during the last quarter. 3.57% of the stock is currently owned by institutional investors and hedge funds.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.